Covenant Asset Management’s Gilead Sciences GILD Stock Holding History

Covenant Asset Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,325	Closed	-$257K	–	140
2018 Q4	$257K	Hold	3,325	–	–	0.13%	122
2018 Q3	$257K	Sell	3,325 -400	-11%	-$30.2K	0.13%	122
2018 Q2	$264K	Buy	3,725 +575	+18%	+$40.6K	0.14%	122
2018 Q1	$237K	Sell	3,150 -200	-6%	-$15.9K	0.14%	122
2017 Q4	$240K	Sell	3,350 -200	-6%	-$15.2K	0.14%	131
2017 Q3	$288K	Hold	3,550	–	–	0.18%	118
2017 Q2	$251K	Sell	3,550 -1,300	-27%	-$86.5K	0.16%	122
2017 Q1	$329K	Sell	4,850 -8,801	-64%	-$619K	0.22%	105
2016 Q4	$978K	Buy	+13,651	New	+$1.01M	0.66%	54

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Covenant Asset Management's GILD Position: Q1 2019 in Review

Covenant Asset Management sold out of Gilead Sciences (GILD) in Q1 2019, closing a stake of 3,325 shares — an estimated $257K sold.

Covenant Asset Management first reported a position in GILD in Q4 2016 and held it in 9 quarters. The position peaked at $978K in Q4 2016. 1,491 funds tracked by Wall St. Rank hold GILD as of Q1 2019.

Covenant Asset Management reported no remaining Gilead Sciences position as of Q1 2019 after selling out during the quarter.
Covenant Asset Management sold 3,325 Gilead Sciences shares in Q1 2019, an estimated $257K.
Covenant Asset Management first reported a position in Gilead Sciences in Q4 2016 and held it in 9 quarters.
Covenant Asset Management's Gilead Sciences position peaked at $978K in Q4 2016.
1,491 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2019.

Based on Covenant Asset Management's 13F filing for Q1 2019, filed 26 Apr 2019.